Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

Wed, 01st May 2024 08:57

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

A host of financial markets in mainland Europe and beyond, including Paris, Frankfurt and Shanghai, are closed for public holidays.

The FTSE 100 index rose 13.69 points, 0.2%, at 8,157.82. The FTSE 250 was up 51.07 points, 0.3%, at 20,135.86, and the AIM All-Share was up 1.36 points, 0.2%, at 764.69.

The Cboe UK 100 was up 0.2% at 814.75, the Cboe UK 250 fell 0.2% to 17,254.36, and the Cboe Small Companies was down 0.1% at 15,720.32.

In New York, the Dow Jones Industrial Average tumbled 1.5% on Tuesday. The S&P 500 lost 1.6% and the Nasdaq Composite plunged 2.0%.

In Tokyo, the Nikkei 225 ended 0.3% on Wednesday. In Sydney, the S&P/ASX 200 slumped 1.2%.

Financial markets in Shanghai and Hong Kong are closed on Wednesday. In Shanghai, they do not re-open until Monday. Financial markets are also closed in Frankfurt, Paris, Madrid and elsewhere in Europe on Wednesday.

The pound was quoted at USD1.2485 early Wednesday, down from USD1.2523 at the time of the London equities close on Tuesday. The euro stood at USD1.0660, down from USD1.0690. Against the yen, the dollar was trading at JPY157.95, up from JPY157.44.

The Fed announces its latest interest rate decision at 1900 BST. It is expected to keep rates on hold this week, with Chair Jerome Powell likely to say that the central bank is not yet confident enough to cut as inflation remains lofty.

"Mood among investors is not cheery into the Federal Reserve's latest monetary policy decision due later today. And it's understandable. The Fed must respond to a three straight month jump in inflation and probably take a step back in its plans to cut the interest rates this year. There is even a risk that the Fed drops the expectation of a rate cut in 2024," Swissquote analyst Ipek Ozkardeskaya commented.

The economic calendar for Wednesday has a UK manufacturing PMI at 0930 BST. In the afternoon, there is the US ADP jobs report at 1315 BST, before the Fed decision in the evening.

The ADP data is expected to show employment in the US private sector grew by 175,000 last month, according to FXStreet cited consensus, easing from 184,000 in March.

The official nonfarm payrolls follow on Friday, with jobs growth of 245,000 expected, easing from 303,000 in March.

Brown Brothers Harriman analysts commented: "Of note, non-farm payrolls has outperformed ADP for eight straight months."

In London, Smith & Nephew shares rose 3.5%, the best large-cap performer. The medical devices maker said first-quarter revenue rose 2.2% on a reported basis to USD1.39 billion from USD1.36 billion.

"Revenue growth in the first quarter was driven by solid performance in our Orthopaedics and Sports Medicine & ENT businesses, partially offset by some anticipated softness in Advanced Wound Management," Chief Executive Officer Deepak Nath said.

"We are confident in our outlook and look forward to all three of our business units contributing as we deliver another year of strong revenue growth."

Smith & Nephew maintained annual guidance, expecting reporting revenue growth of 4.3% to 5.3%.

GSK added 0.7% as it raised annual guidance. Shingles drug, Shingrix, was one stand-out performer in its first-quarter, but the drugmaker reported momentum across all business areas.

Haleon fell 1.9%. GSK's former consumer healthcare business backed yearly guidance, but said reported revenue was lower amid a weaker Covid season in China in the first quarter of the year compared to a year ago.

Next fell 1.0% as it reported a first-quarter that went ahead of plan, but maintained its outlook as it predicts the second-quarter will be more tepid.

In the 13 weeks to April 27, its first-quarter, full price sales rose 5.7% on-year. The outcome was ahead of guidance, with the clothing and homewares seller having predicted growth of 5%.

It still expects pretax profit to grow 4.6% in the full-year to GBP960 million.

Next added: "We are maintaining our guidance for full price sales in the first half to be up 2.5%. This implies that our sales in Q2 will be down -0.3%. We expect the sales performance in the second quarter to be weaker than the first quarter because last year benefited from particularly warm weather from late May through to the end of June."

Aston Martin shares fell 7.6%, the worst mid-cap performer as it recorded weaker results, for a first-quarter of a year it is labelling a "period of transition".

The carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened to GBP138.8 million from GBP74.2 million.

Executive Chair Lawrence Stroll commented: "2024 is a year of immense product transformation at Aston Martin, with the introduction of four new models to the market before the end of the year. Our first quarter performance reflects this expected period of transition, as we ceased production and delivery of our outgoing core models ahead of the ramp up in production of the new Vantage, upgraded DBX707 and our upcoming V12 flagship sports car which we've confirmed today. As part of our ongoing programme of ultra-exclusive models, we will deliver a new Special in the fourth quarter of the year."

It expects a second-quarter performance to be "broadly similar" to the first.

Edison analyst Neil Shah commented: "Looking ahead, despite the current headwinds, AML maintains its 2024 guidance and medium-term targets, with anticipated positive free cash flow generation in H2 and beyond. These results reflect a transformative phase for AML, symbolised by the impending arrival of incoming CEO Adrian Hallmark. His appointment, slated for no later than October, signals a strategic shift as the company navigates a transition away from outgoing models towards a more sustainable future."

On AIM, Trinity Exploration surged 47%. Touchstone Exploration fell 4.4%. Touchstone said it has struck an all-share deal to acquire Trinity.

The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, an oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale".

It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production."

As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity Shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

Brent oil was quoted at USD85.28 a barrel on Wednesday morning London time, down from USD86.42 late Tuesday. Gold was quoted at USD2,285.55 an ounce, down from USD2,298.10.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.